Download Kannan Presentation (PowerPoint)

Raghu Kannan
“THE NEW GOLD STANDARD IN
COMPANION DIAGNOSTICS”
Current methods of detection
IHC: Dako –in accurate
PCR –amplifies all genes
FISH –works well; however, microscopic
visualization of tumor regions is difficult
First Target: NSCLC
Quantify proteins
Quantify genes
Effective treatment plan
Detects and
quantifies
proteins in
tumor tissue.
Lung Cancer (2014)
Incidence 221,200; Mortality: 158,040
The heterogeneity of NSCLC makes effective treatment
dependent on knowledge of the patient’s tumor
biomarkers (and mutations)
Cost of targeted therapy: $100,000
A diagnostic test platform that enables
identification and quantitation of all types of tumor
biomarkers (and mutation) is needed
Platform Technology: Gold
nanorod mediated targeted
histochemistry” (GNR-HC).
Can identify and precisely quantify
biomarkers in human tissues
Highly sensitive.
Can detect and quantify all classes of
tumor biomarkers (e.g., proteins,
mutations, gene fusion, copy number
variants)
Business model.
Diagnostic kit supplied to pathology laboratories.
Oncologists –order to provide effective treatment plan.
Pharmaceutical companies use as companion diagnostics.
Market strategy
Start up: Golden Diagnostics
IDE; PMA pathway
$250K for Pre-IDE phase
$1-$1.5 million for IDE and PMA approval
Raghu Kannan –Business development and
nanotechnology
Co-founder of three start-ups; raised more than $3 million
in funding.
Gerald Arthur –Board Certified Pathologist
Partners and potential partners
Regulatory specialists –Dr. Anandhi Upendran
Industry contacts –Eli Lilly for providing human samples
and expertise